Securing market protection for cell therapies: Patents versus regulatory exclusivity
Cell therapies represent incredibly exciting science and the opportunity to treat previously intractable diseases. Cell therapies...
top of page
Beyond the process: Securing robust IP protection for cell therapies
Cell therapy represents one of the most exciting fields of innovation, with the potential to provide long-term cures for previously...
AlphaFold: From Nobel Prize to drug-discovery gold mine?
AlphaFold, a machine learning model for predicting protein structure, is arguably one of the greatest achievements of AI so far. Whilst...
Strict US written description requirement applied to CAR-T-cell therapy (Juno v Kite)
In the US, functional antibody claims have increasingly failed to satisfy the strict "written description" sufficiency requirement. The...
Functional claims for pharmaceutical formulations: Validity versus enforcement (T 2130/22)
The Board of Appeal decision in T 2130/22 considered the inventive step of a pharmaceutical formulation in which the technical effect...
Falling between the cracks: The challenges of patent strategy for stem cell therapies (T 1259/22)
Cell therapy is a highly innovative therapeutic strategy that uses living cells to combat disease. Cell therapy strategies include stem...
The benefits and pitfalls of drug manufacturing IP (T 2543/22)
The Board of Appeal decision in T 2543/22 relates to a manufacturing method for preparing a therapeutic peptide. The Board of Appeal...
A new mode of administration is a new specific medical use (but not necessarily inventive) (T 0295/22)
The Board of Appeal decision in T 0295/22 tackles the question of whether a new mode of administration of a drug should be considered a...
bottom of page